MECHANISM OF ACTION OF 4-AMINOPYRIDINE IN THE SYMPTOMATIC TREATMENT OF MULTIPLE-SCLEROSIS

被引：16
|
作者：
DAVIS, FA [1 ]
STEFOSKI, D [1 ]
QUANDT, FN [1 ]
机构：
[1] RUSH UNIV,DEPT PHYSIOL,CHICAGO,IL 60612
来源：
ANNALS OF NEUROLOGY | 1995年 / 37卷 / 05期
关键词：
D O I：
10.1002/ana.410370524
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：684 / 684
页数：1
相关论文
共 50 条
  • [11] 4-AMINOPYRIDINE IS SUPERIOR TO 3,4-DIAMINOPYRIDINE IN THE TREATMENT OF PATIENTS WITH MULTIPLE-SCLEROSIS
    POLMAN, CH
    BERTELSMANN, FW
    DEWAAL, R
    VANDIEMEN, HAM
    UITDEHAAG, BMJ
    VANLOENEN, AC
    KOETSIER, JC
    ARCHIVES OF NEUROLOGY, 1994, 51 (11) : 1136 - 1139
  • [12] 4-AMINOPYRIDINE ADMINISTERED ORALLY IMPROVES CLINICAL SIGNS IN MULTIPLE-SCLEROSIS
    DAVIS, FA
    STEFOSKI, D
    BINDOKAS, J
    SCHAUF, CL
    ANNALS OF NEUROLOGY, 1986, 20 (01) : 152 - 152
  • [13] ORALLY-ADMINISTERED 4-AMINOPYRIDINE IMPROVES CLINICAL SIGNS IN MULTIPLE-SCLEROSIS
    DAVIS, FA
    STEFOSKI, D
    RUSH, J
    ANNALS OF NEUROLOGY, 1990, 27 (02) : 186 - 192
  • [14] 10 Questions About 4-Aminopyridine and the Treatment of Multiple Sclerosis
    Bever, Christopher T., Jr.
    NEUROLOGIST, 2009, 15 (03) : 161 - 162
  • [15] 4-AMINOPYRIDINE INDUCES FUNCTIONAL IMPROVEMENT IN MULTIPLE-SCLEROSIS PATIENTS - A NEUROPHYSIOLOGICAL STUDY
    VANDIEMEN, HAM
    POLMAN, CH
    VANDONGEN, MMMM
    NAUTA, JJP
    STRIJERS, RLM
    VANLOENEN, AC
    BERTELSMANN, FW
    KOETSIER, JC
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 1993, 116 (02) : 220 - 226
  • [16] Neuroprotective effects of 4-aminopyridine in multiple sclerosis
    Koska, V.
    Dietrich, M.
    Hecker, C.
    Goettle, P.
    Hilla, A.
    Heskamp, A.
    Lepka, K.
    Issberner, A.
    Baksmeier, C.
    Steckel, J.
    Balk, L.
    Knier, B.
    Korn, T.
    Havla, J.
    Martinez-Lapiscina, E. H.
    Sola, N.
    Manogaran, P.
    Olbert, E. D.
    Schippling, S.
    Cruz-Herranz, A.
    Yiu, H.
    Button, J.
    Caldito, N. Gonzalez
    von Gall, C.
    Mausberg, A. K.
    Stettner, M.
    Zimmermann, H.
    Paul, F.
    Brandt, A. U.
    Kuery, P.
    Goebels, N.
    Aktas, O.
    Berndt, C.
    Saidha, S.
    Green, A. J.
    Calabresi, P. A.
    Fischer, D.
    Hartung, H. -P.
    Albrecht, P.
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 308 - 310
  • [17] 4-AMINOPYRIDINE IN PATIENTS WITH MULTIPLE-SCLEROSIS - DOSAGE AND SERUM LEVEL RELATED TO EFFICACY AND SAFETY
    VANDIEMEN, HAM
    POLMAN, CH
    KOETSIER, JC
    VANLOENEN, AC
    NAUTA, JJP
    BERTELSMANN, FW
    CLINICAL NEUROPHARMACOLOGY, 1993, 16 (03) : 195 - 204
  • [18] THE PHARMACOKINETICS AND TOLERABILITY OF A SLOW-RELEASE FORMULATION OF 4-AMINOPYRIDINE IN MULTIPLE-SCLEROSIS PATIENTS
    BEVER, CT
    YOUNG, D
    TIERNEY, D
    CONWAY, K
    KATZ, E
    COSTELLO, K
    FOSSLER, M
    JOHNSON, KP
    NEUROLOGY, 1995, 45 (04) : A351 - A351
  • [19] THE EFFECTS OF 4-AMINOPYRIDINE ON COGNITIVE FUNCTION IN PATIENTS WITH MULTIPLE-SCLEROSIS - A PILOT-STUDY
    SMITS, RCF
    EMMEN, HH
    BERTELSMANN, FW
    KULIG, BM
    VANLOENEN, AC
    POLMAN, CH
    NEUROLOGY, 1994, 44 (09) : 1701 - 1705
  • [20] Decreased relapses of multiple sclerosis in patients on 4-aminopyridine
    Stefoski, D
    Katsamakis, G
    Ko, M
    MULTIPLE SCLEROSIS, 2004, 10 (7032): : S272 - S273
12345